ADMINISTER VYEPTI® EVERY 12 WEEKS[1]
coordinated by the Vyepti Today™ Patient Support Program

Please see the product monograph for complete dosing recommendations.

Pr Vyepti®

SIGNIFICANTLY REDUCED MONTHLY MIGRAINE DAYS

VS. PLACEBO IN PATIENTS WITH CHRONIC MIGRAINE*

(Primary endpoint: Reduction in mean MMDs from baseline over weeks 1-12; Vyepti® 100 mg -7.7, placebo -5.6, p<0.0001; difference from placebo = -2; CI 95% [-2.9, -1.2])[1,2]

PrVyepti® (eptinezumab for injection) is indicated for the prevention of migraine in adults who have at least 4 migraine days per month. Vyepti® should be prescribed by healthcare professionals experienced in the diagnosis and treatment of migraine.

MMDs=monthly migraine days

***PROMISE-2 Trial:** A parallel-group, double-blind, placebo-controlled global trial to evaluate the efficacy and safety of Vyepti® for the preventive treatment of chronic migraine (defined as ≥15 to ≤26 headache days, of which ≥8 were assessed as migraine days) in adults. A total of 1,072 patients were randomized and received placebo (n=366), eptinezumab 100 mg (n=356), or eptinezumab 300 mg (n=350) every 12 weeks for 24 weeks (2 infusions). The primary endpoint was the change from baseline in mean MMD over weeks 1-12. Key secondary endpoints included the proportion of patients achieving ≥75% reduction in monthly migraine days over weeks 1-12.

Lundbeck

Vyepti® 100 mg demonstrated a significant reduction in mean MMDs from baseline over weeks 1-12 vs. placebo in chronic migraine[1,2]

Reduction of mean MMDs[1,3*]
Weeks 1-12



Adapted from the product monograph.

Clinical use:

- No data are available in the pediatric population (<18 years of age). Therefore, Vyepti® is not authorized for pediatric use.
- The safety and efficacy of Vyepti® has not been established in geriatric patients (≥65 years of age). The clinical study program of Vyepti® did not include sufficient numbers of these patients to determine whether they respond differently from younger patients.

Most serious warnings and precautions:

Hypersensitivity reactions: Serious hypersensitivity reactions, including angioedema, urticaria, rash and anaphylactic reactions have been reported with the CGRP-class products including Vyepti®. These reactions may develop within minutes of the infusion. If a serious hypersensitivity reaction occurs, administration of Vyepti® should be discontinued immediately and appropriate therapy initiated.

MMDs=monthly migraine days

*Baseline was the average over the 28-day screening period prior to receiving treatment. The change in baseline in MMDs (weeks 1-12) was analyzed using ANCOVA with baseline MMDs as covariate and treatment and prophylactic medication use (Yes/No) as fixed effects.

≥75% MMDs reduction from baseline was demonstrated in patients taking Vyepti® vs. placebo (key secondary endpoint)[1,2]

≥75% MMD responder rates[1,3]
Weeks 1-12



Adapted from the product monograph

Other relevant warnings and precautions:

- Patients with cardiovascular diseases
- Patients with diabetes or morbid obesity
- Patients with hereditary fructose intolerance (HFI)
- Hepatic insufficiency
- Patients with HIV, Hepatitis B and C
- Patients with autoimmune disorder
- Patients with neurological disorder
- Renal Insufficiency
- Fertility
- Pregnancy
- Breastfeeding

For more information:

Please consult the **product monograph** at https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/vyepti_product_monograph_english.pdf for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available by calling us at 1-800-586-2325.

†Proportion of patients achieving ≥75% reduction from baseline in monthly migraine days during the specified time frame.

References: 1. Vyepti® Product Monograph. Lundbeck.
2. Lipton RB, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. *Neurology*. 2020 Mar 31;94(13):e1365-e1377.

Vyepti Today™
Patient Support Program

DESIGNED TO SUPPORT THE PATIENT JOURNEY
FROM PRESCRIPTION TO INFUSION

Staffed by qualified healthcare professionals, and reimbursement specialists, the Vyepti TODAY® Patient Support Program assists your Vyepti® patients and coordinates their infusion experience.

One contact + a personal care team

- A dedicated single point of contact for your patient
- Backed by a team of professionals to support your patient's therapy, including a nurse, pharmacist and reimbursement specialist

Treatment initiation support

- Helps your patients get access to their treatment as soon as possible
- Locates your patient's nearest infusion clinic

Financial and reimbursement assistance

- Assistance to complete the required paperwork
- Helps your patients navigate through the reimbursement process

Infusion care and coordination

- Qualified healthcare professionals counsel your patients throughout the Vyepti® infusion journey
- Appointment coordination

Ongoing support

- We're with your patients throughout their treatment
- One-on-one support is available by phone and email

Enroll patients in the Vyepti TODAY® Patient Support Program

Connect with us to get your patients started

Call 1-833-8-VYEPTI (893784) • **Email** support@vyeptitoday.ca • **Fax** 1-833-9-VYEPTI (893784)

Lundbeck

REVIEWED BY PAAB

MEMBER OF INNOVATIVE MEDICINES CANADA

VISIT VYEPTI.CA

CA-VYEP-0373-E